5 Questions Novo Nordisk Needs to Answer to Get Its Stock Moving Higher
Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...
Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs
Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...
Novo, Eli Lilly to dominate global pharma sales in 2025: report
Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...
Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact
Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and ...
5 Questions Novo Nordisk Must Answer to Drive Its Stock Higher
Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...
Better Buy: Novo Nordisk vs. AstraZeneca
Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...
BioSpace2d
Novo Puts $4.6B on the Line to Expand Valo Deal, Maintain Cardiometabolic Leadership
The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...
DPA International on MSN2d
Novo Nordisk expands drug collaboration with Valo Health
Denmark's Novo Nordisk on Wednesday announced an expansion of its collaboration with Valo Health to discover and develop ...
Novo Nordisk: Be Greedy When Others Are Fearful
Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...
Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M
Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...